# OnCo record neuroendocrine-differentiation (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/neuroendocrine-differentiation/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "neuroendocrine-differentiation" ;
  schema:name "Neuroendocrine differentiation in prostate cancer"@en ;
  schema:alternateName "NED"@en, "neuroendocrine differentiation"@en, "treatment-emergent neuroendocrine differentiation"@en, "Paneth cell-like change"@en, "chromogranin positive prostate cancer"@en, "synaptophysin positive prostate cancer"@en ;
  schema:description "Prostate cancer cells that have taken on the look and the markers of nerve-and-hormone cells. A trace of it is present in almost every prostate cancer and means nothing; a tumour made mostly of it is a different and much more serious disease, and it usually appears after years of hormone treatment."@en ;
  schema:url <https://onco.cc/terms/neuroendocrine-differentiation/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1097/pas.0000000000000208>, <https://doi.org/10.1111/his.14711>, <https://tumourclassification.iarc.who.int/chapters/36>, <https://www.rcpath.org/static/8cc88604-2c8d-4df4-a99542df41c102af/G084-dataset-for-histopathology-reports-for-prostatic-carcinoma.pdf> ;
  onco:tag "gu", "prostate-glossary" ;
  onco:related <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/cancers/prostate-nepc/>, <https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/>, <https://onco.cc/key-papers/paper-aggarwal-t-sccpc-jco-2018/>, <https://onco.cc/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-nepc/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/hormonal/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/terms/ihc/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/androgen-receptor/> ;
  onco:pathways <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/> ;
  onco:terms <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/prostate-acinar-adenocarcinoma/>, <https://onco.cc/terms/gleason-grade-group/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/>, <https://onco.cc/key-papers/paper-aggarwal-t-sccpc-jco-2018/>, <https://onco.cc/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/> .